Around half the world’s population is considered to be affected by Helicobacter pylori (H. pylori). H. pylori infection is considered to be the main cause of chronic gastritis and peptic ulcer disease although only a small proportion of those infected with H. pylori develops related diseases. A number of studies have suggested that the oral cavity is a reservoir for H. pylori. Although colonisation and growth of H. pylori may be different in the mouth and stomach it has been suggested that periodontal therapy may be a potentially effective adjunctive treatment for gastric H. pylori infection.
The main aim of this Cochrane review was to assess the effects of periodontal therapy plus eradication therapy versus eradication therapy alone for gastric H. pylori infection.
Methods Searches were conducted in the Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase, the Chinese Biomedical Database, ClinicalTrials.gov and the WHO ICTRP portal. Randomised controlled trials (RCTs) comparing periodontal therapy plus eradication therapy versus eradication therapy alone were considered. Two reviewers independently selected studies, abstracted data and assessed study quality using the Cochrane risk of bias tool. The data were pooled using both fixed-effect and random-effects models and results calculated as odds ratios (OR) with their 95% confidence intervals (CIs) based on an intention-to-treat analysis.
Continue reading original content HERE: